Advertisement

Current Hepatology Reports

, Volume 18, Issue 2, pp 164–173 | Cite as

HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials

  • Maria Gabriela Delgado
  • Jaume Bosch
Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Portal Hypertension

Abstract

Purpose of Review

Update current knowledge of the use of hepatic venous pressure gradient (HVPG) as a predictor of clinical events and of efficacy of therapy for portal hypertension.

Recent Findings

HVPG is a good predictor of clinical events. Decrease in HVPG during therapy is accompanied by a decreased incidence of complications from portal hypertension and improved survival.

Summary

HVPG measurements are a valuable tool in the management of portal hypertension in cirrhosis. In addition of detecting and grading the severity of portal hypertension, HVPG measurements provide robust prognostic information on the risk of complications, disease progression/regression, and survival. Changes in HVPG in response to therapy predict the effects on clinical outcomes, both during treatment with beta-blockers and when treating HCV-related cirrhosis with specific antivirals. This has led to suggest that HVPG can be used as a surrogate for clinical events when developing new therapies for portal hypertension. Limitations of this approach are discussed.

Keywords

HVPG Portal hypertension Surrogate for clinical events Clinical trials New therapies 

Notes

Compliance with Ethical Standards

Conflict of Interest

Jaume Bosch reports personal fees from Conatus, personal fees from Gilead, grants and personal fees from Exallenz, personal fees from Actelion, personal fees from BioVie, grants from Brudy, other from BLB, and personal fees from Blade Therapeutics, outside the submitted work. Maria Gabriela Delgado declares no potential conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bosch J, Garcia-Pagan JC, Berzigotti A, Abraldes JG. Measurement of portal pressure and its role in the management of chronic liver disease. Semin Liver Dis. 2006;26(4):348–62.CrossRefPubMedGoogle Scholar
  2. 2.
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39(2):280–2.CrossRefPubMedGoogle Scholar
  3. 3.
    Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6(10):573–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Reverter E, Blasi A, Abraldes JG, Martinez-Palli G, Seijo S, Turon F, et al. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2014;34(1):16–25.CrossRefPubMedGoogle Scholar
  5. 5.
    Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254–61.CrossRefPubMedGoogle Scholar
  6. 6.
    Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50(5):923–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362(9):823–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Gluud C, Brok J, Gong Y, Koretz RL. Hepatology may have problems with putative surrogate outcome measures. J Hepatol. 2007;46(4):734–42.CrossRefPubMedGoogle Scholar
  10. 10.
    •• de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52. Current guidelines on the management of portal hypertension. CrossRefGoogle Scholar
  11. 11.
    •• Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–35. Guidance document on the current management of portal hypertension. CrossRefPubMedGoogle Scholar
  12. 12.
    Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol. 2006;44(1):111–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl. 2007;13(9):1305–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology. 2009;49(4):1236–44.CrossRefPubMedGoogle Scholar
  16. 16.
    D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Ripoll C, Bari K, Garcia-Tsao G. Serum albumin can identify patients with compensated cirrhosis with a good prognosis. J Clin Gastroenterol. 2015;49(7):613–9.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    • Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015;61(2):526–36. Evidence for using HVPG in selecting candidates for liver resection. CrossRefPubMedGoogle Scholar
  19. 19.
    • Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155(4):1140–53. Use of HVPG as a marker of disease progression in NASH. CrossRefPubMedGoogle Scholar
  20. 20.
    Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int. 2012;32(9):1407–14.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Merkel C, Bolognesi M, Bellon S, Zuin R, Noventa F, Finucci G, et al. Prognostic usefulness of hepatic vein catheterization in patients with cirrhosis and esophageal varices. Gastroenterology. 1992;102(3):973–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Berzigotti A, Rossi V, Tiani C, Pierpaoli L, Zappoli P, Riili A, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol. 2011;46(5):687–95.CrossRefPubMedGoogle Scholar
  23. 23.
    • Silva-Junior G, Baiges A, Turon F, Torres F, Hernandez-Gea V, Bosch J, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015;62(5):1584–92. Importance of accurate technique in HVPG measurements. CrossRefPubMedGoogle Scholar
  24. 24.
    Stanley AJ, Robinson I, Forrest EH, Jones AL, Hayes PC. Haemodynamic parameters predicting variceal haemorrhage and survival in alcoholic cirrhosis. QJM. 1998;91(1):19–25.CrossRefPubMedGoogle Scholar
  25. 25.
    Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54(2):555–61.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Rincon D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48(4):487–95.CrossRefPubMedGoogle Scholar
  27. 27.
    Lens S, Rincon D, Garcia-Retortillo M, Albillos A, Calleja JL, Banares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13(10):1846–53 e1.CrossRefPubMedGoogle Scholar
  28. 28.
    Moitinho E, Escorsell A, Bandi JC, Salmeron JM, Garcia-Pagan JC, Rodes J, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology. 1999;117(3):626–31.CrossRefPubMedGoogle Scholar
  29. 29.
    Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garci APJC, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2008;48(2):229–36.CrossRefPubMedGoogle Scholar
  30. 30.
    Rincon D, Lo Iacono O, Ripoll C, Gomez-Camarero J, Salcedo M, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25(7):841–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Navasa M, Garcia-Pagan JC, Bosch J, Riera JR, Banares R, Mas A, et al. Portal hypertension in acute liver failure. Gut. 1992;33(7):965–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    •• Villanueva C, Graupera I, Aracil C, Alvarado E, Minana J, Puente A, et al. A randomized trial to assess whether portal pressure guided therapy to prevent variceal rebleeding improves survival in cirrhosis. Hepatology. 2017;65(5):1693–707. Randomized clinical trial showing superiority of HVPG guided over standard of care medical therapy for portal hypertension. CrossRefPubMedGoogle Scholar
  33. 33.
    • Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62(1 Suppl):S121–30. Review of evolving mechanisms of portal hypertension during the progression of cirrhosis. CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology. 2000;31(5):1061–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet. 1995;346(8982):1056–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Grace ND, Conn HO, Resnick RH, Groszmann RJ, Atterbury CE, Wright SC, et al. Distal splenorenal vs. portal-systemic shunts after hemorrhage from varices: a randomized controlled trial. Hepatology. 1988;8(6):1475–81.CrossRefPubMedGoogle Scholar
  37. 37.
    Rigau J, Bosch J, Bordas JM, Navasa M, Mastai R, Kravetz D, et al. Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. Gastroenterology. 1989;96(3):873–80.CrossRefPubMedGoogle Scholar
  38. 38.
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology. 1990;99(5):1401–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology. 2003;37(4):902–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med. 1996;334(25):1624–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med. 2001;345(9):647–55.CrossRefPubMedGoogle Scholar
  42. 42.
    Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell’Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol. 2006;101(3):506–12.CrossRefPubMedGoogle Scholar
  43. 43.
    Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzalez B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol. 2004;40(5):757–65.CrossRefPubMedGoogle Scholar
  44. 44.
    La Mura V, Abraldes JG, Raffa S, Retto O, Berzigotti A, Garcia-Pagan JC, et al. Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. J Hepatol. 2009;51(2):279–87.CrossRefPubMedGoogle Scholar
  45. 45.
    Villanueva C, Aracil C, Colomo A, Hernandez-Gea V, Lopez-Balaguer JM, Alvarez-Urturi C, et al. Acute hemodynamic response to beta-blockers and prediction of long-term outcome in primary prophylaxis of variceal bleeding. Gastroenterology. 2009;137(1):119–28.CrossRefPubMedGoogle Scholar
  46. 46.
    Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol. 2007;102(5):1116–26.CrossRefPubMedGoogle Scholar
  47. 47.
    D’Amico G, Garcia-Pagan JC, Luca A, Bosch J. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131(5):1611–24.CrossRefPubMedGoogle Scholar
  48. 48.
    Kerbert AJ, Chiang FW, van der Werf M, Stijnen T, Slingerland H, Verspaget HW, et al. Hemodynamic response to primary prophylactic therapy with nonselective beta-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(4):380–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Bellot P, Garcia-Pagan JC, Abraldes JG, Bosch J. Primary prophylaxis of esophageal variceal bleeding in cirrhosis. Gastroenterol Clin Biol. 2008;32(5 Pt 1):532–40.CrossRefPubMedGoogle Scholar
  50. 50.
    Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology. 1999;30(1):79–83.CrossRefPubMedGoogle Scholar
  51. 51.
    Banares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36(6):1367–73.CrossRefPubMedGoogle Scholar
  52. 52.
    Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634–41.CrossRefPubMedGoogle Scholar
  53. 53.
    Bosch J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology. 2010;51(6):2214–8.CrossRefPubMedGoogle Scholar
  54. 54.
    Schwarzer R, Kivaranovic D, Paternostro R, Mandorfer M, Reiberger T, Trauner M, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47(8):1162–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Bureau C, Peron JM, Alric L, Morales J, Sanchez J, Barange K, et al. "a La carte" treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36(6):1361–6.CrossRefPubMedGoogle Scholar
  56. 56.
    Thalheimer U, Mela M, Patch D, Burroughs AK. Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut. 2004;53(1):143–8.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Monescillo A, Martinez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jimenez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004;40(4):793–801.CrossRefPubMedGoogle Scholar
  58. 58.
    Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370–9.CrossRefPubMedGoogle Scholar
  59. 59.
    •• Hernandez-Gea V, Procopet B, Giraldez A, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2018. Larger study on early use of TIPS for variceal bleeding in high-risk patients. Google Scholar
  60. 60.
    Garcia-Pagan JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58(1):45–50.CrossRefPubMedGoogle Scholar
  61. 61.
    Cucchetti A, Cescon M, Golfieri R, Piscaglia F, Renzulli M, Neri F, et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol. 2016;64(1):79–86.CrossRefPubMedGoogle Scholar
  62. 62.
    Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30(6):1434–40.CrossRefPubMedGoogle Scholar
  63. 63.
    Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996;111(4):1018–22.CrossRefPubMedGoogle Scholar
  64. 64.
    •• Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–50. Current guidelines for management of hepatocellular carcinoma. CrossRefGoogle Scholar
  65. 65.
    •• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. Current guidelines for management of hepatocellular carcinoma. CrossRefGoogle Scholar
  66. 66.
    Perez-Paramo M, Munoz J, Albillos A, Freile I, Portero F, Santos M, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology. 2000;31(1):43–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Reiberger T, Ferlitsch A, Payer BA, Mandorfer M, Heinisch BB, Hayden H, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911–21.CrossRefPubMedGoogle Scholar
  68. 68.
    • Lens S, Alvarado-Tapias E, Marino Z, Londono MC, LLop E, Martinez J, et al. Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. 2017;153(5):1273–83 e1. Large study on effects of anti-HCV therapy on HVPG. CrossRefPubMedGoogle Scholar
  69. 69.
    Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, et al. Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. 2017;24(10):823–31.CrossRefPubMedGoogle Scholar
  70. 70.
    van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMedGoogle Scholar
  71. 71.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51(2):422–30.CrossRefPubMedGoogle Scholar
  72. 72.
    Schwarzer R, Kivaranovic D, Mandorfer M, Paternostro R, Wolrab D, Heinisch B, et al. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertension. Aliment Pharmacol Ther. 2018;47(1):86–94.CrossRefPubMedGoogle Scholar
  73. 73.
    Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C. Adipokines in liver cirrhosis. Int J Mol Sci. 2017;18(7).Google Scholar
  74. 74.
    Iacobini C, Menini S, Ricci C, Blasetti Fantauzzi C, Scipioni A, Salvi L, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol. 2011;54(5):975–83.CrossRefPubMedGoogle Scholar
  75. 75.
    Nomoto K, Nishida T, Nakanishi Y, Fujimoto M, Takasaki I, Tabuchi Y, et al. Deficiency in galectin-3 promotes hepatic injury in CDAA diet-induced nonalcoholic fatty liver disease. TheScientificWorldJournal. 2012;2012:959824.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Pejnovic N, Jeftic I, Jovicic N, Arsenijevic N, Lukic ML. Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis. World J Gastroenterol. 2016;22(44):9706–17.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Chalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, et al. A multicenter, randomized, double-blind, PLB-controlled trial of galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension. J Hepatol. 2018;68:S100–1.CrossRefGoogle Scholar
  78. 78.
    Garcia-Tsao G, Fuchs M, Shiffman M, Borg BB, Pyrsopoulos N, Shetty K, et al. Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. Hepatology. 2019;69(2):717–28.Google Scholar
  79. 79.
    Villanueva C, Genescà J, Garcia-Pagan J, Calleja J, Aracil C, Bañares R, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;18:1–12.CrossRefGoogle Scholar
  80. 80.
    Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Comparison of balloon vs. straight catheter for the measurement of portal hypertension. Aliment Pharmacol Ther. 2010;32(11–12):1351–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Perello A, Escorsell A, Bru C, Gilabert R, Moitinho E, Garcia-Pagan JC, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology. 1999;30(6):1393–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Steinlauf AF, Garcia-Tsao G, Zakko MF, Dickey K, Gupta T, Groszmann RJ. Low-dose midazolam sedation: an option for patients undergoing serial hepatic venous pressure measurements. Hepatology. 1999;29(4):1070–3.CrossRefPubMedGoogle Scholar
  83. 83.
    Abraldes JG, Albillos A, Banares R, Turnes J, Gonzalez R, Garcia-Pagan JC, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136(5):1651–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Maria Gabriela Delgado
    • 1
  • Jaume Bosch
    • 1
    • 2
  1. 1.Swiss Liver Center, Hepatology, University Clinic for Visceral Surgery and Medicine, Inselspital, Department of Biomedical ResearchUniversity of BernBerneSwitzerland
  2. 2.Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, CiberehdUniversity of BarcelonaBarcelonaSpain

Personalised recommendations